Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19

Jevalikar et al., Scientific Reports, doi:10.1038/s41598-021-85809-y (date from preprint)
Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 82% Improvement Relative Risk ICU admission 34% Oxygen therapy 32% Vitamin D  Jevalikar et al.  LATE TREATMENT Is late treatment with vitamin D beneficial for COVID-19? Prospective study of 197 patients in India Lower mortality (p=0.12) and ICU admission (p=0.29), not sig. c19early.org Jevalikar et al., Scientific Reports, Dec 2020 Favorsvitamin D Favorscontrol 0 0.5 1 1.5 2+
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020, now with p < 0.00000000001 from 122 studies, recognized in 9 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
Prospective study of 410 hospitalized patients in India showing lower mortality and ICU admission with cholecalciferol treatment, although not statistically significant with the small number of cases. The median total dose was 60,000IU.
No significant difference was found for outcomes based on baseline vitamin D deficiency, however this analysis does not appear to account for the deficient patients that were treated with vitamin D.
Cholecalciferol was used in this study. Meta analysis shows that late stage treatment with calcitriol / calcifediol (or paricalcitol, alfacalcidol, etc.) is more effective than cholecalciferol: 69% [47‑82%] lower risk vs. 39% [27‑49%] lower risk. Cholecalciferol requires two hydroxylation steps to become activated - first in the liver to calcifediol, then in the kidney to calcitriol. Calcitriol, paricalcitol, and alfacalcidol are active vitamin D analogs that do not require conversion. This allows them to have more rapid onset of action compared to cholecalciferol. The time delay for cholecalciferol to increase serum calcifediol levels can be 2-3 days, and the delay for converting calcifediol to active calcitriol can be up to 7 days.
Bolus treatment is less effective. Pharmacokinetics and the potential side effects of high bolus doses suggest that ongoing treatment spread over time is more appropriate. Research has confirmed that lower dose regular treatment with vitamin D is more effective than intermittent high-dose bolus treatment for various conditions, including rickets and acute respiratory infections1,2. The biological mechanisms supporting these findings involve the induction of enzymes such as 24-hydroxylase and fibroblast growth factor 23 (FGF23) by high-dose bolus treatments. These enzymes play roles in inactivating vitamin D, which can paradoxically reduce levels of activated vitamin D and suppress its activation for extended periods post-dosage. Evidence indicates that 24-hydroxylase activity may remain elevated for several weeks following a bolus dose, leading to reduced levels of the activated form of vitamin D. Additionally, FGF23 levels can increase for at least three months after a large bolus dose, which also contributes to the suppression of vitamin D activation1.
This is the 16th of 122 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 587 sextillion).
30 studies are RCTs, which show efficacy with p=0.0000032.
risk of death, 82.0% lower, RR 0.18, p = 0.12, treatment 1 of 128 (0.8%), control 3 of 69 (4.3%), NNT 28.
risk of ICU admission, 33.7% lower, RR 0.66, p = 0.29, treatment 16 of 128 (12.5%), control 13 of 69 (18.8%), NNT 16.
risk of oxygen therapy, 31.7% lower, RR 0.68, p = 0.06, treatment 38 of 128 (29.7%), control 30 of 69 (43.5%), NNT 7.3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jevalikar et al., 28 Dec 2020, prospective, India, peer-reviewed, 8 authors, dosage 60,000IU single dose, median total dose.
This PaperVitamin DAll
Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19
Ganesh Jevalikar, Ambrish Mithal, Anshu Singh, Rutuja Sharma, Khalid J Farooqui, Shama Mahendru, Arun Dewan, Sandeep Budhiraja
Scientific Reports, doi:10.1038/s41598-021-85809-y
Vitamin D deficiency (VDD) owing to its immunomodulatory effects is believed to influence outcomes in COVID-19. We conducted a prospective, observational study of patients, hospitalized with COVID-19. Serum 25-OHD level < 20 ng/mL was considered VDD. Patients were classified as having mild and severe disease on basis of the WHO ordinal scale for clinical improvement (OSCI). Of the 410 patients recruited, patients with VDD (197,48.2%) were significantly younger and had lesser comorbidities. The levels of PTH were significantly higher in the VDD group (63.5 ± 54.4 vs. 47.5 ± 42.9 pg/mL). The proportion of severe cases (13.2% vs.14.6%), mortality (2% vs. 5.2%), oxygen requirement (34.5% vs.43.4%), ICU admission (14.7% vs.19.8%) was not significantly different between patients with or without VDD. There was no significant correlation between serum 25-OHD levels and inflammatory markers studied. Serum parathormone levels correlated with D-dimer (r 0.117, p-0.019), ferritin (r 0.132, p-0.010), and LDH (r 0.124, p-0.018). Amongst VDD patients, 128(64.9%) were treated with oral cholecalciferol (median dose of 60,000 IU). The proportion of severe cases, oxygen, or ICU admission was not significantly different in the treated vs. untreated group. In conclusion, serum 25-OHD levels at admission did not correlate with inflammatory markers, clinical outcomes, or mortality in hospitalized COVID-19 patients. Treatment of VDD with cholecalciferol did not make any difference to the outcomes.
Author contributions G.J. drafted the study protocol, supervised patient enrollment, analyzed data, wrote the first draft of the manuscript, and will be the corresponding author for the manuscript. A.M. conceptualized the study, guided the study protocol, and critically reviewed the manuscript. A.S. supervised collection and reporting of laboratory investigations and contributed to the data collection. R.S., K.J.F., S.M. contributed to the data collection and analysis. K.J.F. reviewed the study protocol. A.D., S.B. critically reviewed the manuscript along with A.M. Competing interests The authors declare no competing interests.
References
Adams, Hewison, Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity, Nat. Clin. Pract. Endocrinol. Metab
Ali, Role of vitamin D in preventing of COVID-19 infection, progression and severity, J. Infect. Public Health
Baktash, Vitamin D status and outcomes for hospitalised older patients with COVID-19, Postgrad. Med. J, doi:10.1136/postgradmedj-2020-138712
Cannell, Epidemic influenza and vitamin D, Epidemiol. Infect
Carpagnano, Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19, J. Endocrinol. Invest, doi:10.1007/s40618-020-01370-x
Cereda, Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital, Clin. Nutr, doi:10.1016/j.clnu.2020.10.055
Guan, Clinical characteristics of Coronavirus disease 2019 in China, N. Engl. J. Med
Hansdottir, Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state, J. Immunol
Hernández, Vitamin D status in hospitalized patients with SARS-CoV-2 infection, J. Clin. Endocrinol. Metab, doi:10.1210/clinem/dgaa733
Holick, Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline, J. Clin. Endocrinol. Metab
Ilie, Stefanescu, Smith, The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality, Aging Clin. Exp. Res, doi:10.1007/s40520-020-01570-8
Jain, Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers, Sci. Rep
Karahan, Katkat, Impact of serum 25(OH) vitamin D level on mortality in patients with COVID-19 in Turkey, J. Nutr. Health Aging
Liu, Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response, Science
Maghbooli, Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection, PLoS ONE, doi:10.1371/journal.pone.0239799
Martineau, Forouhi, Vitamin D for COVID-19: A case to answer?, Lancet Diabetes Endocrinol
Martineau, Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data, BMJ
Mithal, Global vitamin D status and determinants of hypovitaminosis D, Osteoporos. Int
Murai, Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2020.26848
Ohaegbulam, Swalih, Patel, Smith, Perrin, Vitamin D supplementation in COVID-19 patients: A clinical case series, Am J Ther, doi:10.1097/MJT.0000000000001222
Padhi, Suvankar, Panda, Pati, Panda, Lower levels of vitamin D are associated with SARS-CoV-2 infection and mortality in the Indian population: An observational study, Int. Immunopharmacol
Panagiotou, Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity, Clin. Endocrinol, doi:10.1111/cen.14276
Pham, Rahman, Majidi, Waterhouse, Neale, Acute respiratory tract infection and 25-hydroxyvitamin D concentration: A systematic review and meta-analysis, Int. J. Environ. Res. Public Health, doi:10.3390/ijerph16173020
Pizzini, Impact of vitamin D deficiency on COVID-19: A prospective analysis from the CovILD registry, Nutrients, doi:10.3390/nu12092775
Radujkovic, Vitamin D deficiency and outcome of COVID-19 patients, Nutrients, doi:10.3390/nu12092757
Rastogi, Short term, high-dose vitamin D supplementation for COVID-19 disease: A randomised, placebo-controlled, study (SHADE study), Postgraduate Med. J, doi:10.1136/postgradmedj-2020-139065
Rhodes, Subramanian, Laird, Kenny, low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity, Aliment. Pharmacol. Ther, doi:10.1111/apt.15777
Samaddar, Gadepalli, Nag, Misra, The enigma of low COVID-19 fatality rate in India, Front. Genet
Wu, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan China, JAMA Intern. Med, doi:10.1001/jamainternmed.2020.0994
Xiao, Vitamin D supplementation for the prevention of childhood acute respiratory infections: A systematic review of randomised controlled trials, Br. J. Nutr
{ 'indexed': {'date-parts': [[2024, 3, 1]], 'date-time': '2024-03-01T17:29:54Z', 'timestamp': 1709314194645}, 'reference-count': 32, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 3, 18]], 'date-time': '2021-03-18T00:00:00Z', 'timestamp': 1616025600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2021, 3, 18]], 'date-time': '2021-03-18T00:00:00Z', 'timestamp': 1616025600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Vitamin D deficiency (VDD) owing to its ' 'immunomodulatory effects is believed to influence outcomes in COVID-19. We conducted a ' 'prospective, observational study of patients, hospitalized with COVID-19. Serum 25-OHD ' 'level\u2009&lt;\u200920\xa0ng/mL was considered VDD. Patients were classified as having mild ' 'and severe disease on basis of the WHO ordinal scale for clinical improvement (OSCI). Of the ' '410 patients recruited, patients with VDD (197,48.2%) were significantly younger and had ' 'lesser comorbidities. The levels of PTH were significantly higher in the VDD group (63.5\u2009' '±\u200954.4 vs. 47.5\u2009±\u200942.9\xa0pg/mL). The proportion of severe cases (13.2% ' 'vs.14.6%), mortality (2% vs. 5.2%), oxygen requirement (34.5% vs.43.4%), ICU admission (14.7% ' 'vs.19.8%) was not significantly different between patients with or without VDD. There was no ' 'significant correlation between serum 25-OHD levels and inflammatory markers studied. Serum ' 'parathormone levels correlated with D-dimer (r 0.117, p- 0.019), ferritin (r 0.132, p-0.010), ' 'and LDH (r 0.124, p-0.018). Amongst VDD patients, 128(64.9%) were treated with oral ' 'cholecalciferol (median dose of 60,000\xa0IU). The proportion of severe cases, oxygen, or ICU ' 'admission was not significantly different in the treated vs. untreated group. In conclusion, ' 'serum 25-OHD levels at admission did not correlate with inflammatory markers, clinical ' 'outcomes, or mortality in hospitalized COVID-19 patients. Treatment of VDD with ' 'cholecalciferol did not make any difference to the outcomes.</jats:p>', 'DOI': '10.1038/s41598-021-85809-y', 'type': 'journal-article', 'created': {'date-parts': [[2021, 3, 18]], 'date-time': '2021-03-18T16:47:41Z', 'timestamp': 1616086061000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 42, 'title': 'Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality ' 'in Indian patients hospitalized for COVID-19', 'prefix': '10.1038', 'volume': '11', 'author': [ {'given': 'Ganesh', 'family': 'Jevalikar', 'sequence': 'first', 'affiliation': []}, {'given': 'Ambrish', 'family': 'Mithal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anshu', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rutuja', 'family': 'Sharma', 'sequence': 'additional', 'affiliation': []}, {'given': 'Khalid J.', 'family': 'Farooqui', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shama', 'family': 'Mahendru', 'sequence': 'additional', 'affiliation': []}, {'given': 'Arun', 'family': 'Dewan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sandeep', 'family': 'Budhiraja', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 3, 18]]}, 'reference': [ { 'key': '85809_CR1', 'unstructured': 'Coronavirus Update (Live): 63,198,955 Cases and 1,467,506 Deaths from ' 'COVID-19 Virus Pandemic—Worldometer. ' 'https://www.worldometers.info/coronavirus/. Accessed 30 Nov 2020.'}, { 'key': '85809_CR2', 'doi-asserted-by': 'publisher', 'first-page': '1129', 'DOI': '10.1017/S0950268806007175', 'volume': '134', 'author': 'JJ Cannell', 'year': '2006', 'unstructured': 'Cannell, J. J. et al. Epidemic influenza and vitamin D. Epidemiol. ' 'Infect. 134, 1129–1140 (2006).', 'journal-title': 'Epidemiol. Infect.'}, { 'key': '85809_CR3', 'doi-asserted-by': 'publisher', 'first-page': 'i6583', 'DOI': '10.1136/bmj.i6583', 'volume': '356', 'author': 'AR Martineau', 'year': '2017', 'unstructured': 'Martineau, A. R. et al. Vitamin D supplementation to prevent acute ' 'respiratory tract infections: Systematic review and meta-analysis of ' 'individual participant data. BMJ 356, i6583 (2017).', 'journal-title': 'BMJ'}, { 'key': '85809_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.3390/ijerph16173020', 'volume': '16', 'author': 'H Pham', 'year': '2019', 'unstructured': 'Pham, H., Rahman, A., Majidi, A., Waterhouse, M. & Neale, R. E. Acute ' 'respiratory tract infection and 25-hydroxyvitamin D concentration: A ' 'systematic review and meta-analysis. Int. J. Environ. Res. Public Health ' '16, 1. https://doi.org/10.3390/ijerph16173020 (2019).', 'journal-title': 'Int. J. Environ. Res. Public Health'}, { 'key': '85809_CR5', 'doi-asserted-by': 'publisher', 'first-page': '1026', 'DOI': '10.1017/S000711451500207X', 'volume': '114', 'author': 'L Xiao', 'year': '2015', 'unstructured': 'Xiao, L. et al. Vitamin D supplementation for the prevention of ' 'childhood acute respiratory infections: A systematic review of ' 'randomised controlled trials. Br. J. Nutr. 114, 1026–1034 (2015).', 'journal-title': 'Br. J. Nutr.'}, { 'key': '85809_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1770', 'DOI': '10.1126/science.1123933', 'volume': '311', 'author': 'PT Liu', 'year': '2006', 'unstructured': 'Liu, P. T. et al. Toll-like receptor triggering of a vitamin D-mediated ' 'human antimicrobial response. Science 311, 1770–1773 (2006).', 'journal-title': 'Science'}, { 'key': '85809_CR7', 'doi-asserted-by': 'publisher', 'first-page': '80', 'DOI': '10.1038/ncpendmet0716', 'volume': '4', 'author': 'JS Adams', 'year': '2008', 'unstructured': 'Adams, J. S. & Hewison, M. Unexpected actions of vitamin D: New ' 'perspectives on the regulation of innate and adaptive immunity. Nat. ' 'Clin. Pract. Endocrinol. Metab. 4, 80–90 (2008).', 'journal-title': 'Nat. Clin. Pract. Endocrinol. Metab.'}, { 'key': '85809_CR8', 'doi-asserted-by': 'publisher', 'first-page': '965', 'DOI': '10.4049/jimmunol.0902840', 'volume': '184', 'author': 'S Hansdottir', 'year': '2010', 'unstructured': 'Hansdottir, S. et al. Vitamin D decreases respiratory syncytial virus ' 'induction of NF-kappaB-linked chemokines and cytokines in airway ' 'epithelium while maintaining the antiviral state. J. Immunol. 184, ' '965–974 (2010).', 'journal-title': 'J. Immunol.'}, { 'key': '85809_CR9', 'doi-asserted-by': 'publisher', 'first-page': '1708', 'DOI': '10.1056/NEJMoa2002032', 'volume': '382', 'author': 'W-J Guan', 'year': '2020', 'unstructured': 'Guan, W.-J. et al. Clinical characteristics of Coronavirus disease 2019 ' 'in China. N. Engl. J. Med. 382, 1708–1720 (2020).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '85809_CR10', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1001/jamainternmed.2020.0994', 'volume': '1', 'author': 'C Wu', 'year': '2020', 'unstructured': 'Wu, C. et al. Risk factors associated with acute respiratory distress ' 'syndrome and death in patients with coronavirus disease 2019 pneumonia ' 'in Wuhan China. JAMA Intern. Med. 1, 1. ' 'https://doi.org/10.1001/jamainternmed.2020.0994 (2020).', 'journal-title': 'JAMA Intern. Med.'}, { 'key': '85809_CR11', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1111/apt.15777', 'volume': '1', 'author': 'JM Rhodes', 'year': '2020', 'unstructured': 'Rhodes, J. M., Subramanian, S., Laird, E. & Kenny, R. A. low population ' 'mortality from COVID-19 in countries south of latitude 35 degrees North ' 'supports vitamin D as a factor determining severity. Aliment. Pharmacol. ' 'Ther. 1, 1. https://doi.org/10.1111/apt.15777 (2020).', 'journal-title': 'Aliment. Pharmacol. Ther.'}, { 'key': '85809_CR12', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1007/s40520-020-01570-8', 'volume': '1', 'author': 'PC Ilie', 'year': '2020', 'unstructured': 'Ilie, P. C., Stefanescu, S. & Smith, L. The role of vitamin D in the ' 'prevention of coronavirus disease 2019 infection and mortality. Aging ' 'Clin. Exp. Res. 1, 1. https://doi.org/10.1007/s40520-020-01570-8 (2020).', 'journal-title': 'Aging Clin. Exp. Res.'}, { 'key': '85809_CR13', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1111/cen.14276', 'volume': '1', 'author': 'G Panagiotou', 'year': '2020', 'unstructured': 'Panagiotou, G. et al. Low serum 25-hydroxyvitamin D (25[OH]D) levels in ' 'patients hospitalised with COVID-19 are associated with greater disease ' 'severity. Clin. Endocrinol. 1, 1. https://doi.org/10.1111/cen.14276 ' '(2020).', 'journal-title': 'Clin. Endocrinol.'}, { 'key': '85809_CR14', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.3390/nu12092757', 'volume': '12', 'author': 'A Radujkovic', 'year': '2020', 'unstructured': 'Radujkovic, A. et al. Vitamin D deficiency and outcome of COVID-19 ' 'patients. Nutrients 12, 1. https://doi.org/10.3390/nu12092757 (2020).', 'journal-title': 'Nutrients'}, { 'key': '85809_CR15', 'doi-asserted-by': 'publisher', 'first-page': '20191', 'DOI': '10.1038/s41598-020-77093-z', 'volume': '10', 'author': 'A Jain', 'year': '2020', 'unstructured': 'Jain, A. et al. Analysis of vitamin D level among asymptomatic and ' 'critically ill COVID-19 patients and its correlation with inflammatory ' 'markers. Sci. Rep. 10, 20191 (2020).', 'journal-title': 'Sci. Rep.'}, { 'key': '85809_CR16', 'doi-asserted-by': 'publisher', 'first-page': '735', 'DOI': '10.1016/S2213-8587(20)30268-0', 'volume': '8', 'author': 'AR Martineau', 'year': '2020', 'unstructured': 'Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: A case to ' 'answer?. Lancet Diabetes Endocrinol. 8, 735–736 (2020).', 'journal-title': 'Lancet Diabetes Endocrinol.'}, { 'key': '85809_CR17', 'doi-asserted-by': 'publisher', 'first-page': '1807', 'DOI': '10.1007/s00198-009-0954-6', 'volume': '20', 'author': 'A Mithal', 'year': '2009', 'unstructured': 'Mithal, A. et al. Global vitamin D status and determinants of ' 'hypovitaminosis D. Osteoporos. Int. 20, 1807–1820 (2009).', 'journal-title': 'Osteoporos. Int.'}, { 'key': '85809_CR18', 'doi-asserted-by': 'publisher', 'first-page': '854', 'DOI': '10.3389/fgene.2020.00854', 'volume': '11', 'author': 'A Samaddar', 'year': '2020', 'unstructured': 'Samaddar, A., Gadepalli, R., Nag, V. L. & Misra, S. The enigma of low ' 'COVID-19 fatality rate in India. Front. Genet. 11, 854 (2020).', 'journal-title': 'Front. Genet.'}, { 'key': '85809_CR19', 'unstructured': 'COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf. ' 'https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf. ' 'Accessed Nov 6 2020.'}, { 'key': '85809_CR20', 'doi-asserted-by': 'publisher', 'first-page': '1373', 'DOI': '10.1016/j.jiph.2020.06.021', 'volume': '13', 'author': 'N Ali', 'year': '2020', 'unstructured': 'Ali, N. Role of vitamin D in preventing of COVID-19 infection, ' 'progression and severity. J. Infect. Public Health 13, 1373–1380 (2020).', 'journal-title': 'J. Infect. Public Health'}, { 'key': '85809_CR21', 'doi-asserted-by': 'publisher', 'first-page': '1911', 'DOI': '10.1210/jc.2011-0385', 'volume': '96', 'author': 'MF Holick', 'year': '2011', 'unstructured': 'Holick, M. F. et al. Evaluation, treatment, and prevention of vitamin D ' 'deficiency: An Endocrine Society clinical practice guideline. J. Clin. ' 'Endocrinol. Metab. 96, 1911–1930 (2011).', 'journal-title': 'J. Clin. Endocrinol. Metab.'}, { 'key': '85809_CR22', 'doi-asserted-by': 'publisher', 'first-page': '107001', 'DOI': '10.1016/j.intimp.2020.107001', 'volume': '88', 'author': 'S Padhi', 'year': '2020', 'unstructured': 'Padhi, S., Suvankar, S., Panda, V. K., Pati, A. & Panda, A. K. Lower ' 'levels of vitamin D are associated with SARS-CoV-2 infection and ' 'mortality in the Indian population: An observational study. Int. ' 'Immunopharmacol. 88, 107001 (2020).', 'journal-title': 'Int. Immunopharmacol.'}, { 'key': '85809_CR23', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1371/journal.pone.0239799', 'volume': '15', 'author': 'Z Maghbooli', 'year': '2020', 'unstructured': 'Maghbooli, Z. et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D ' 'at least 30 ng/mL reduced risk for adverse clinical outcomes in patients ' 'with COVID-19 infection. PLoS ONE 15, 1. ' 'https://doi.org/10.1371/journal.pone.0239799 (2020).', 'journal-title': 'PLoS ONE'}, { 'key': '85809_CR24', 'first-page': '1', 'volume': '1', 'author': 'S Karahan', 'year': '2020', 'unstructured': 'Karahan, S. & Katkat, F. Impact of serum 25(OH) vitamin D level on ' 'mortality in patients with COVID-19 in Turkey. J. Nutr. Health Aging 1, ' '1–8 (2020).', 'journal-title': 'J. Nutr. Health Aging'}, { 'key': '85809_CR25', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1136/postgradmedj-2020-138712', 'volume': '1', 'author': 'V Baktash', 'year': '2020', 'unstructured': 'Baktash, V. et al. Vitamin D status and outcomes for hospitalised older ' 'patients with COVID-19. Postgrad. Med. J. 1, 1. ' 'https://doi.org/10.1136/postgradmedj-2020-138712 (2020).', 'journal-title': 'Postgrad. Med. J.'}, { 'key': '85809_CR26', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1007/s40618-020-01370-x', 'volume': '1', 'author': 'GE Carpagnano', 'year': '2020', 'unstructured': 'Carpagnano, G. E. et al. Vitamin D deficiency as a predictor of poor ' 'prognosis in patients with acute respiratory failure due to COVID-19. J. ' 'Endocrinol. Invest. 1, 1. https://doi.org/10.1007/s40618-020-01370-x ' '(2020).', 'journal-title': 'J. Endocrinol. Invest.'}, { 'key': '85809_CR27', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1016/j.clnu.2020.10.055', 'volume': '1', 'author': 'E Cereda', 'year': '2020', 'unstructured': 'Cereda, E. et al. Vitamin D 25OH deficiency in COVID-19 patients ' 'admitted to a tertiary referral hospital. Clin. Nutr. 1, 1. ' 'https://doi.org/10.1016/j.clnu.2020.10.055 (2020).', 'journal-title': 'Clin. Nutr.'}, { 'key': '85809_CR28', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1210/clinem/dgaa733', 'volume': '1', 'author': 'JL Hernández', 'year': '2020', 'unstructured': 'Hernández, J. L. et al. Vitamin D status in hospitalized patients with ' 'SARS-CoV-2 infection. J. Clin. Endocrinol. Metab. 1, 1. ' 'https://doi.org/10.1210/clinem/dgaa733 (2020).', 'journal-title': 'J. Clin. Endocrinol. Metab.'}, { 'key': '85809_CR29', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.3390/nu12092775', 'volume': '12', 'author': 'A Pizzini', 'year': '2020', 'unstructured': 'Pizzini, A. et al. Impact of vitamin D deficiency on COVID-19: A ' 'prospective analysis from the CovILD registry. Nutrients 12, 1. ' 'https://doi.org/10.3390/nu12092775 (2020).', 'journal-title': 'Nutrients'}, { 'key': '85809_CR30', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1136/postgradmedj-2020-139065', 'volume': '1', 'author': 'A Rastogi', 'year': '2020', 'unstructured': 'Rastogi, A. et al. Short term, high-dose vitamin D supplementation for ' 'COVID-19 disease: A randomised, placebo-controlled, study (SHADE study). ' 'Postgraduate Med. J. 1, 1. ' 'https://doi.org/10.1136/postgradmedj-2020-139065 (2020).', 'journal-title': 'Postgraduate Med. J.'}, { 'issue': '5', 'key': '85809_CR31', 'doi-asserted-by': 'publisher', 'first-page': 'e485', 'DOI': '10.1097/MJT.0000000000001222', 'volume': '27', 'author': 'KC Ohaegbulam', 'year': '2020', 'unstructured': 'Ohaegbulam, K. C., Swalih, M., Patel, P., Smith, M. A. & Perrin, R. ' 'Vitamin D supplementation in COVID-19 patients: A clinical case series. ' 'Am J Ther. 27(5), e485–e490. ' 'https://doi.org/10.1097/MJT.0000000000001222 (2020).', 'journal-title': 'Am J Ther.'}, { 'key': '85809_CR32', 'doi-asserted-by': 'publisher', 'unstructured': 'Murai, IH. et al.\xa0Effect of a Single High Dose of Vitamin D3 on ' 'Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A ' 'Randomized Clinical Trial. JAMA. \xa02021 Feb 17:e2026848. ' 'https://doi.org/10.1001/jama.2020.26848 (2020).\xa0', 'DOI': '10.1001/jama.2020.26848'}], 'container-title': 'Scientific Reports', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41598-021-85809-y.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-021-85809-y', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-021-85809-y.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 12, 3]], 'date-time': '2022-12-03T05:23:36Z', 'timestamp': 1670045016000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-021-85809-y'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 3, 18]]}, 'references-count': 32, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2021, 12]]}}, 'alternative-id': ['85809'], 'URL': 'http://dx.doi.org/10.1038/s41598-021-85809-y', 'relation': { 'has-preprint': [ { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-129238/v1', 'asserted-by': 'object'}]}, 'ISSN': ['2045-2322'], 'subject': ['Multidisciplinary'], 'container-title-short': 'Sci Rep', 'published': {'date-parts': [[2021, 3, 18]]}, 'assertion': [ { 'value': '15 December 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '3 March 2021', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '18 March 2021', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'The authors declare no competing interests.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '6258'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit